Early detection and prognostication are crucial for improving cancer outcomes. This session will examine the latest advancements in cancer biomarkers, including circulating tumor DNA, exosomes, and proteomics. Discussions will focus on the clinical utility of biomarkers in screening, diagnosing minimal residual disease, predicting treatment responses, and monitoring disease progression. Emphasis will be placed on integrating biomarker data with imaging and clinical parameters to enhance precision in oncology practice.